Sedative-Hypnotic Toxicity Differential Diagnoses

1. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016 Mar. 81 (3):412-9. [Medline].

2. Weaver MF. Prescription Sedative Misuse and Abuse. Yale J Biol Med. 2015 Sep. 88 (3):247-56. [Medline].

3. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterthaler KM, Banner W. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila). 2018 Dec. 56 (12):1213-1415. [Medline]. [Full Text].

4. Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015 May 1. 150:1-13. [Medline].

5. European Monitoring Centre of Drugs and Drug Addiction. The misuse of benzodiazepines among high-risk opioid users in Europe (Perspectives on drugs). EMCDDA.europa.eu. Available at http://www.emcdda.europa.eu/publications/pods/benzodiazepines. June 2018; Accessed: February 7, 2019.

6. Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017 May 1. 174:58-64. [Medline]. [Full Text].

7. Jay SJ, Johanson WG Jr, Pierce AK. Respiratory complications of overdose with sedative drugs. Am Rev Respir Dis. 1975 Nov. 112(5):591-8. [Medline].

8. Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan. 118 (1):37-44. [Medline]. [Full Text].

9. Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 Mar. 81 (3):428-36. [Medline]. [Full Text].

10. An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 6. 188 (17-18):E537. [Medline]. [Full Text].

11. Buckley NA, McManus PR. Changes in fatalities due to overdose of anxiolytic and sedative drugs in the UK (1983-1999). Drug Saf. 2004. 27(2):135-41. [Medline].

12. Barnett R, Grace M, Boothe P, et al. Flumazenil in drug overdose: randomized, placebo-controlled study to assess cost effectiveness. Crit Care Med. 1999 Jan. 27(1):78-81. [Medline].

13. Bledsoe BE. No more coma cocktails. Using science to dispel myths & improve patient care. JEMS. 2002 Nov. 27(11):54-60. [Medline].

14. Clark RF, Sage TA, Tunget C, Manoguerra AS. Delayed onset lorazepam poisoning successfully reversed by flumazenil in a child. Case report and review of the literature. Pediatr Emerg Care. 1995 Feb. 11(1):32-4. [Medline].

15. Tintinalli JE, et al, eds. Emergency Medicine: A Comprehensive Study Guide. 4th ed. New York: McGraw-Hill; 1995.

16. Rosen P, Barkin R, et al, eds. Emergency Medicine: Concepts and Clinical Practice. 3rd ed. St Louis: Mosby-Year Book; 1996.

17. Giri AK, Banerjee S. Genetic toxicology of four commonly used benzodiazepines: a review. Mutat Res. 1996 Jun. 340(2-3):93-108. [Medline].

18. Greenberg DA, Simon RP. Flexor and extensor postures in sedative drug-induced coma. Neurology. 1982 Apr. 32(4):448-51. [Medline].

19. Hamad A, Sharma N. Acute zolpidem overdose leading to coma and respiratory failure. Intensive Care Med. 2001 Jul. 27(7):1239. [Medline].

20. Hojer J, Salmonson H, Sundin P. Zaleplon-induced coma and bluish-green urine: possible antidotal effect by flumazenil. J Toxicol Clin Toxicol. 2002. 40(5):571-2. [Medline].

21. Isbister GK, O'Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004 Jul. 58(1):88-95. [Medline].

22. Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry. 2004 Aug. 43(8):927-8. [Medline].

23. Lovett B, Watts D, Grossman M. Prolonged coma after eszopiclone overdose. Am J Emerg Med. 2007 Jul. 25(6):735.e5-6. [Medline].

Jeffrey S Cooper, MD, FAAEM, FACEP Faculty Attending Physician, Department of Emergency Medicine, University of Nebraska Medical Center; Medical Director, Hyperbaric Medicine Center, The Nebraska Medical Center

Jeffrey S Cooper, MD, FAAEM, FACEP is a member of the following medical societies: Undersea and Hyperbaric Medical Society, Wilderness Medical Society, American College of Emergency Physicians

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Michael J Burns, MD Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center

Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Lance W Kreplick, MD, FAAEM, MMM, UHM Staff Physician, Teladoc Health; President and Chief Executive Officer, QED Medical Solutions, LLC

Lance W Kreplick, MD, FAAEM, MMM, UHM is a member of the following medical societies: American Academy of Emergency Medicine, American Association for Physician Leadership

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article